

(19) World Intellectual Property
Organization
International Bureau



549790

(43) International Publication Date
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number
WO 2004/083189 A1

(51) International Patent Classification⁷: **C07D 249/08**,
249/10, A61K 31/4196, A61P 25/00

[US/US]; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US). **WEAVER, Damian** [US/US]; 126 East
Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).

(21) International Application Number:

PCT/US2004/007597

(74) Common Representative: **MERCK & CO., INC.**; 126
East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(22) International Filing Date: 12 March 2004 (12.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/455,952 18 March 2003 (18.03.2003) US

(71) Applicant (for all designated States except US): **MERCK
& CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway,
New Jersey 07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHAKRAVARTY,
Prasun, K.** [US/US]; 126 East Lincoln Avenue, Rahway,
New Jersey 07065-0907 (US). **FISHER, Michael, H.**
[US/US]; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US). **PALUCKI, Brenda** [US/US]; 126 East
Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).
PARK, Min, K. [KR/US]; 126 East Lincoln Avenue, Rah-
way, New Jersey 07065-0907 (US). **PARSONS, William,
H.** [US/US]; 126 East Lincoln Avenue, Rahway, New
Jersey 07065-0907 (US). **ZHOU, Bishan** [CN/US]; 126
East Lincoln Avenue, Rahway, New Jersey 07065-0907
(US). **CAREY, James, P.** [US/US]; 126 East Lincoln Av-
enue, Rahway, New Jersey 07065-0907 (US). **FRANTZ,
Douglas, E.** [US/US]; 126 East Lincoln Avenue, Rahway,
New Jersey 07065-0907 (US). **KRESS, Michael, H.**

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS

(57) Abstract: Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier.



WO 2004/083189 A1